Noticias de CRVS_US

Noticias del mercado

Últimas noticias sobre CRVS_US — 126 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: CRVS_US ✕ 126 resultados
09/04/2026 CRVS_US — Xã Châu Thành
Is Corvus (CRVS) Stock a Good Buy in 2026 | CRVS Q4 Earnings: Misses Estimates by $0.02 - Investment Rating
09/04/2026 CRVS_US — tayninh.gov.vn
Is Corvus (CRVS) Stock a Good Buy in 2026 | CRVS Q4 Earnings: Misses Estimates by $0.02 - Investment Rating
08/04/2026 CRVS_US — Seeking Alpha
Corvus Pharmaceuticals: Strong Clinical Narrative, Already Priced For Success
06/04/2026 CRVS_US — MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Analysts
02/04/2026 CRVS_US — MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Below Fifty Day Moving Average - What's Next?
26/03/2026 CRVS_US — Stock Titan
Vanguard amends ownership for Corvus Pharmaceuticals (NASDAQ: CRVS) after realignment
13/03/2026 CRVS_US — Stock Titan ES ← EN
Corvus Pharmaceuticals (NASDAQ:CRVS) lanza un programa de acciones en el mercado de 200 millones de dólares
13/03/2026 CRVS_US — TradingView
Corvus Pharmaceuticals Expands ATM Equity Program to $200 Million With Jefferies
13/03/2026 CRVS_US — TipRanks
Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline
12/03/2026 CRVS_US — Investing.com
Corvus Pharmaceuticals rises on atopic dermatitis trial data By Investing.com
12/03/2026 CRVS_US — Yahoo Finance
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
12/03/2026 CRVS_US — Stock Titan
Corvus eczema drug posts positive early data and $189M cash boost
12/03/2026 CRVS_US — Investing.com
Corvus Pharmaceuticals rises on atopic dermatitis trial data
12/03/2026 CRVS_US — Investing.com
Earnings call transcript: Corvus Pharmaceuticals Q4 2025 Misses EPS Forecast
12/03/2026 CRVS_US — GuruFocus
Decoding Corvus Pharmaceuticals Inc (CRVS): A Strategic SWOT Ins
12/03/2026 CRVS_US — Investing.com
Corvus Pharmaceuticals earnings on deck after positive trial data
12/03/2026 CRVS_US — IndexBox
Corvus Pharmaceuticals 2025 Financial Report: Quarterly & Annual Results | CRVS - News and Statistics
12/03/2026 CRVS_US — TradingView
Corvus Pharmaceuticals 10‑K: $0 Revenue, $(0.19) EPS (basic) — net loss $(15.28M)
12/03/2026 CRVS_US — MarketBeat
Corvus Pharmaceuticals Q4 2025 Earnings Call Transcript
06/03/2026 CRVS_US — The Manila Times
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Página 6 de 7

keyboard_arrow_up